The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome

Jinwook Hwang, Myoung H. Kang, Young A. Yoo, Yu H. Quan, Hyun Koo Kim, Sang Cheul Oh, Young Ho Choi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Researchers in recent studies have reported that the sonic hedgehog (Shh) signaling pathway plays a crucial role during tumorigenesis, angiogenesis and cellular differentiation. We investigated the clinical and pathological significances of the Shh pathway and of its lymphangiogenic components in non-small-cell lung cancer (NSCLC), namely, Shh, glioma-associated oncogene homolog zinc finger protein 1 (Gli1), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and vascular endothelial growth factor D (VEGF-D). Methods: The expression of Shh, Gli1, LYVE-1 and VEGF-D in primary NSCLC tissue from 40 patients was examined using immunohistochemical assays, and relationships between expression and clinicopathological data, such as age, gender, histology, tumor size, nodal stage, visceral pleural invasion, lymphatic thromboembolism, recurrence and overall survival were investigated. Results: Of the 40 specimens examined, 25 (62.5%), 20 (50.0%), 11 (27.5%) and 20 (50.0%) were positive for Shh, Gli1, LYVE-1 or VEGF-D expression, respectively. The expression of Gli1 and LYVE-1 were significantly associated (P = 0.011), and Shh and LYVE-1 expression was related to visceral pleural invasion and lymphatic thromboembolism, respectively (P < 0.05). Shh expression levels compared on survival curves were statistically significant in univariate logrank analysis (P = 0.020). However, other clinicopathological factors did not reveal any statistical significance in univariate and multivariate analyses. Conclusions: To our knowledge, this the first report of the relationship between components of the Shh signaling pathway and prognosis in NSCLC. The expression of Shh, Gli1 and LYVE-1 was found to be associated with clinicopathological factors and survival. Thus, the overexpression of the Shh signaling pathway could serve as a predictor of malignant behavior, including lymphangiogenesis, in NSCLC.

Original languageEnglish
Article number268
JournalWorld Journal of Surgical Oncology
Volume12
Issue number1
DOIs
Publication statusPublished - 2014 Aug 21

Fingerprint

CD44 Antigens
Lymphatic Vessels
Non-Small Cell Lung Carcinoma
Vascular Endothelial Growth Factor D
Thromboembolism
Survival
Lymphangiogenesis
Zinc Fingers
Oncogenes
Glioma
Histology
Carcinogenesis
Multivariate Analysis
Research Personnel
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome. / Hwang, Jinwook; Kang, Myoung H.; Yoo, Young A.; Quan, Yu H.; Kim, Hyun Koo ; Oh, Sang Cheul; Choi, Young Ho.

In: World Journal of Surgical Oncology, Vol. 12, No. 1, 268, 21.08.2014.

Research output: Contribution to journalArticle

@article{87f15663a73d440abb04021786e1849e,
title = "The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome",
abstract = "Background: Researchers in recent studies have reported that the sonic hedgehog (Shh) signaling pathway plays a crucial role during tumorigenesis, angiogenesis and cellular differentiation. We investigated the clinical and pathological significances of the Shh pathway and of its lymphangiogenic components in non-small-cell lung cancer (NSCLC), namely, Shh, glioma-associated oncogene homolog zinc finger protein 1 (Gli1), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and vascular endothelial growth factor D (VEGF-D). Methods: The expression of Shh, Gli1, LYVE-1 and VEGF-D in primary NSCLC tissue from 40 patients was examined using immunohistochemical assays, and relationships between expression and clinicopathological data, such as age, gender, histology, tumor size, nodal stage, visceral pleural invasion, lymphatic thromboembolism, recurrence and overall survival were investigated. Results: Of the 40 specimens examined, 25 (62.5{\%}), 20 (50.0{\%}), 11 (27.5{\%}) and 20 (50.0{\%}) were positive for Shh, Gli1, LYVE-1 or VEGF-D expression, respectively. The expression of Gli1 and LYVE-1 were significantly associated (P = 0.011), and Shh and LYVE-1 expression was related to visceral pleural invasion and lymphatic thromboembolism, respectively (P < 0.05). Shh expression levels compared on survival curves were statistically significant in univariate logrank analysis (P = 0.020). However, other clinicopathological factors did not reveal any statistical significance in univariate and multivariate analyses. Conclusions: To our knowledge, this the first report of the relationship between components of the Shh signaling pathway and prognosis in NSCLC. The expression of Shh, Gli1 and LYVE-1 was found to be associated with clinicopathological factors and survival. Thus, the overexpression of the Shh signaling pathway could serve as a predictor of malignant behavior, including lymphangiogenesis, in NSCLC.",
keywords = "Gli1, Hedgehog pathway, LYVE-1, NSCLC, Prognosis, Sonic hedgehog, VEGF-D",
author = "Jinwook Hwang and Kang, {Myoung H.} and Yoo, {Young A.} and Quan, {Yu H.} and Kim, {Hyun Koo} and Oh, {Sang Cheul} and Choi, {Young Ho}",
year = "2014",
month = "8",
day = "21",
doi = "10.1186/1477-7819-12-268",
language = "English",
volume = "12",
journal = "World Journal of Surgical Oncology",
issn = "1477-7819",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome

AU - Hwang, Jinwook

AU - Kang, Myoung H.

AU - Yoo, Young A.

AU - Quan, Yu H.

AU - Kim, Hyun Koo

AU - Oh, Sang Cheul

AU - Choi, Young Ho

PY - 2014/8/21

Y1 - 2014/8/21

N2 - Background: Researchers in recent studies have reported that the sonic hedgehog (Shh) signaling pathway plays a crucial role during tumorigenesis, angiogenesis and cellular differentiation. We investigated the clinical and pathological significances of the Shh pathway and of its lymphangiogenic components in non-small-cell lung cancer (NSCLC), namely, Shh, glioma-associated oncogene homolog zinc finger protein 1 (Gli1), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and vascular endothelial growth factor D (VEGF-D). Methods: The expression of Shh, Gli1, LYVE-1 and VEGF-D in primary NSCLC tissue from 40 patients was examined using immunohistochemical assays, and relationships between expression and clinicopathological data, such as age, gender, histology, tumor size, nodal stage, visceral pleural invasion, lymphatic thromboembolism, recurrence and overall survival were investigated. Results: Of the 40 specimens examined, 25 (62.5%), 20 (50.0%), 11 (27.5%) and 20 (50.0%) were positive for Shh, Gli1, LYVE-1 or VEGF-D expression, respectively. The expression of Gli1 and LYVE-1 were significantly associated (P = 0.011), and Shh and LYVE-1 expression was related to visceral pleural invasion and lymphatic thromboembolism, respectively (P < 0.05). Shh expression levels compared on survival curves were statistically significant in univariate logrank analysis (P = 0.020). However, other clinicopathological factors did not reveal any statistical significance in univariate and multivariate analyses. Conclusions: To our knowledge, this the first report of the relationship between components of the Shh signaling pathway and prognosis in NSCLC. The expression of Shh, Gli1 and LYVE-1 was found to be associated with clinicopathological factors and survival. Thus, the overexpression of the Shh signaling pathway could serve as a predictor of malignant behavior, including lymphangiogenesis, in NSCLC.

AB - Background: Researchers in recent studies have reported that the sonic hedgehog (Shh) signaling pathway plays a crucial role during tumorigenesis, angiogenesis and cellular differentiation. We investigated the clinical and pathological significances of the Shh pathway and of its lymphangiogenic components in non-small-cell lung cancer (NSCLC), namely, Shh, glioma-associated oncogene homolog zinc finger protein 1 (Gli1), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and vascular endothelial growth factor D (VEGF-D). Methods: The expression of Shh, Gli1, LYVE-1 and VEGF-D in primary NSCLC tissue from 40 patients was examined using immunohistochemical assays, and relationships between expression and clinicopathological data, such as age, gender, histology, tumor size, nodal stage, visceral pleural invasion, lymphatic thromboembolism, recurrence and overall survival were investigated. Results: Of the 40 specimens examined, 25 (62.5%), 20 (50.0%), 11 (27.5%) and 20 (50.0%) were positive for Shh, Gli1, LYVE-1 or VEGF-D expression, respectively. The expression of Gli1 and LYVE-1 were significantly associated (P = 0.011), and Shh and LYVE-1 expression was related to visceral pleural invasion and lymphatic thromboembolism, respectively (P < 0.05). Shh expression levels compared on survival curves were statistically significant in univariate logrank analysis (P = 0.020). However, other clinicopathological factors did not reveal any statistical significance in univariate and multivariate analyses. Conclusions: To our knowledge, this the first report of the relationship between components of the Shh signaling pathway and prognosis in NSCLC. The expression of Shh, Gli1 and LYVE-1 was found to be associated with clinicopathological factors and survival. Thus, the overexpression of the Shh signaling pathway could serve as a predictor of malignant behavior, including lymphangiogenesis, in NSCLC.

KW - Gli1

KW - Hedgehog pathway

KW - LYVE-1

KW - NSCLC

KW - Prognosis

KW - Sonic hedgehog

KW - VEGF-D

UR - http://www.scopus.com/inward/record.url?scp=84910063173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910063173&partnerID=8YFLogxK

U2 - 10.1186/1477-7819-12-268

DO - 10.1186/1477-7819-12-268

M3 - Article

C2 - 25141859

AN - SCOPUS:84910063173

VL - 12

JO - World Journal of Surgical Oncology

JF - World Journal of Surgical Oncology

SN - 1477-7819

IS - 1

M1 - 268

ER -